{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:05:05Z","timestamp":1762430705498},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.encep.2012.10.009","type":"journal-article","created":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T23:30:12Z","timestamp":1355355012000},"page":"S22-S28","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S1","title":["Surveillance m\u00e9tabolique biologique apr\u00e8s initiation d\u2019un traitement antipsychotique chez des personnes trait\u00e9es par lithium ou anticonvulsivants"],"prefix":"10.1016","volume":"39","author":[{"given":"H.","family":"Verdoux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Gaudron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.-R.","family":"Auleley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Deligne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Blum-Boisgard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Thi\u00e9baut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2012.10.009_bib0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","author":"American Psychiatric Association","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2012.10.009_bib0010","first-page":"197","article-title":"Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics","volume":"33","author":"De Nayer","year":"2007","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2012.10.009_bib0015","first-page":"S112","article-title":"\u2018Schizophrenia and Diabetes 2003\u2019 expert consensus meeting, Dublin, 3\u20134\u00a0October 2003: consensus summary","volume":"47","author":"Expert Consensus Meeting","year":"2004","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.encep.2012.10.009_bib0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0013-7006(05)82368-1","article-title":"Assessment of metabolic impairments inducted by atypical antipsychotics among schizophrenic patients","volume":"31","author":"Gauth\u00e9","year":"2005","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2012.10.009_bib0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.encep.2009.10.008","article-title":"Metabolic side effects of risperidone in early onset schizophrenia","volume":"36","author":"Goeb","year":"2010","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2012.10.009_bib0030","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.encep.2008.10.014","article-title":"Drawing up guidelines for the attendance of physical health of patients with severe mental illness","volume":"35","author":"Saravane","year":"2009","journal-title":"Enc\u00e9phale"},{"key":"10.1016\/j.encep.2012.10.009_bib0035","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1176\/appi.ajp.162.6.1217","article-title":"Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications","volume":"162","author":"Straker","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2012.10.009_bib0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1176\/appi.ajp.2008.08030383","article-title":"Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents","volume":"166","author":"Haupt","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2012.10.009_bib0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archgenpsychiatry.2009.179","article-title":"Metabolic testing rates in 3\u00a0state Medicaid programs after FDA warnings and ADA\/APA recommendations for second-generation antipsychotic drugs","volume":"67","author":"Morrato","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.encep.2012.10.009_bib0050","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/schbul\/sbm038","article-title":"A UK audit of screening for the metabolic side effects of antipsychotics in community patients","volume":"33","author":"Barnes","year":"2007","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.encep.2012.10.009_bib0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1192\/bjp.185.2.152","article-title":"Testing for diabetes in hospitalised patients prescribed antipsychotic drugs","volume":"185","author":"Taylor","year":"2004","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.encep.2012.10.009_bib0060","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2337\/dc08-1720","article-title":"Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes","volume":"32","author":"Morrato","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.encep.2012.10.009_bib0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jad.2007.01.006","article-title":"Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder","volume":"102","author":"Kilbourne","year":"2007","journal-title":"J Affect Disord"},{"key":"10.1016\/j.encep.2012.10.009_bib0070","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4088\/JCP.v69n0219","article-title":"Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data","volume":"69","author":"Morrato","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2012.10.009_bib0075","series-title":"About the ATC\/DDD system","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2007"},{"key":"10.1016\/j.encep.2012.10.009_bib0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-0029-1237396","article-title":"Antipsychotics use pattern in persons initially treated with mood-stabilizers: a naturalistic study","volume":"43","author":"Verdoux","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.encep.2012.10.009_bib0085","series-title":"Stata Statistical Software: release 11.0","author":"StataCorp","year":"2009"},{"key":"10.1016\/j.encep.2012.10.009_bib0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-244X-7-28","article-title":"A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients","volume":"7","author":"Mackin","year":"2007","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.encep.2012.10.009_bib0095","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.eurpsy.2007.10.007","article-title":"Awareness of metabolic concerns in patients with bipolar disorder: a survey of European psychiatrists","volume":"23","author":"Bauer","year":"2008","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.encep.2012.10.009_bib0100","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.jcp.0000142281.85207.d5","article-title":"The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists","volume":"24","author":"Newcomer","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2012.10.009_bib0105","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.encep.2012.10.009_bib0110","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National trends in the outpatient treatment of children and adolescents with antipsychotic drugs","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.encep.2012.10.009_bib0115","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eurpsy.2008.12.007","article-title":"Trends in costs of antipsychotics in France","volume":"24","author":"Verdoux","year":"2009","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.encep.2012.10.009_bib0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0447.2008.01203.x","article-title":"Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme","volume":"118","author":"Barnes","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.encep.2012.10.009_bib0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-244X-9-80","article-title":"Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration","volume":"9","author":"Shi","year":"2009","journal-title":"BMC Psychiatry"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001370061200276X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001370061200276X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T03:00:22Z","timestamp":1540004422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001370061200276X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":25,"alternative-id":["S001370061200276X"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2012.10.009","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}